Oral Testosterone Therapy Jatenzo Faces CV, Sampling Tube Issues At Advisory Cmte
US FDA questions Clarus product's long-term safety in briefing documents for Bone, Reproductive and Urologic Drugs Advisory Committee meeting.
You may also be interested in...
US FDA advisory committee worries about off-label use of Lipocine's Tlando and Clarus' Jatenzo.
Two oral testosterone therapies solicited similar concerns, but sometimes different votes from advisory committee members on recommending approval.
FDA's advisory committee voted down Lipocine's Tlando and Clarus' Jatenzo based on concerns about off-label use, but if they do reach the market, Tlando's lack of titration could pose problems for physicians, while both drugs could raise difficulties with the types of tubing used to test testosterone concentrations.